3PBIOVIAN and Eleva Partner to Advance Biologics Manufacturing with Moss-Based Technology

• 3PBIOVIAN will provide production capacity for clinical-grade material for Eleva’s Factor H (CPV-104) program, which is set to enter clinical trials in the first half of 2025.

• Eleva grants 3PBIOVIAN a non-exclusive license to its moss-based expression system, expanding its manufacturing capabilities for biologics.

3PBIOVIAN and Eleva have formed a strategic alliance to advance the manufacturing of clinical-grade biologics, including Eleva’s Factor H (CPV-104) program. Under the agreement, 3PBIOVIAN, a contract development and manufacturing organisation (CDMO), will provide production capacity to support Eleva’s clinical pipeline. Factor H (CPV-104), a novel complement modulator, is being developed for C3 Glomerulopathy (C3G) and dry age-related macular degeneration (dry AMD) and is expected to enter its first clinical trial in the first half of 2025.

The partnership also grants 3PBIOVIAN a non-exclusive license to Eleva’s proprietary moss-based expression system, allowing the CDMO to enhance its biologics manufacturing capabilities. This collaboration aims to increase the visibility and market penetration of Eleva’s platform while expanding 3PBIOVIAN’s production capabilities for complex biologics.

“With 3PBIOVIAN, we have secured a renowned and high-quality manufacturing partner to support our pipeline expansion strategy,” said Dr. Andreas Schaaf, CSO and Managing Director of Eleva. “As our current programs advance towards and through clinical studies, forward-looking planning of production capacity is a crucial success factor.”

Dámaso Molero Sánchez, Group CEO at 3PBIOVIAN, added: “We are delighted that Eleva has selected us as a partner for the manufacturing of clinical material for their current pipeline programs, including their novel complement regulator Factor H (CPV-104), which could provide patients with a much-needed new therapeutic option. Access to Eleva’s expression system also supports our commitment to meet the evolving needs of biopharmaceutical developers by continuously expanding our capabilities. Moss-based expression adds a valuable new dimension to our established high-quality offerings in biologics manufacturing. ”

Eleva’s moss-based manufacturing platform enables GMP production at a pre-commercial scale, with up to 2,000-litre capacity using standard fermenter equipment. Through this alliance, Eleva aims to scale its clinical and commercial manufacturing capabilities, while both companies will jointly promote the technology to future partners and clients.